Register to Access

Focus on percutaneous short-term ventricular assist devices: joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices - Part 1. Why, how and when percutaneous ventricular assist device support?

28 January 2022, from 18:00 to 19:00 CET Europe/Paris Focus on percutaneous short-term ventricular assist devices: joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices - Part 1. Why, how and when percutaneous ventricular assist device support? Access event page https://esc365.escardio.org/event/369 2022-01-28T18:00:00 2022-01-28T19:00:00
logo

Organiser: European Association of Percutaneous Cardiovascular Interventions (EAPCI)

Topic: Interventional Cardiology

Host: Doctor A. Chieffo (Milan, IT)

Speakers: Professor H. Thiele (Leipzig, DE) , Associate Professor G. Tarantini (Padua, IT)

Webinar

Registration

Add to calendar Europe/Paris Focus on percutaneous short-term ventricular assist devices: joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices - Part 1. Why, how and when percutaneous ventricular assist device support? Access event page https://esc365.escardio.org/event/369 2022-01-28T18:00:00 2022-01-28T19:00:00

Hosts & Speakers

Doctor Alaide Chieffo

IRCCS San Raffaele Hospital, Milan (Italy)

Role: Host

Professor Holger Thiele

Heart Center Leipzig at University of Leipzig, Leipzig (Germany)

Role: Speaker

Associate Professor Giuseppe Tarantini

University Hospital of Padova, Padua (Italy)

Role: Speaker

Related content

EHRA Premium Access

A stitch in time saves nine : Urgent Left main PCI in a patient with refractory angina.

29 December 2021

A stitch in time saves nine : Urgent Left main PCI in a patient with refractory angina.

29 December 2021

A stitch in time saves nine : Urgent Left main PCI in a patient with refractory angina.

29 December 2021

A stitch in time saves nine : Urgent Left main PCI in a patient with refractory angina.

29 December 2021

This platform is supported by

logo Novo Nordisk